Peter Attia· MD
and now we have the new guy on the street this ben pedoic acid which is a weaker cholesterol synthesis inhibitor affecting an early on cholesterol synthesis step also that has mendelian randomization support
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and now we have the new guy on the street this ben pedoic acid which is a weaker cholesterol synthesis inhibitor affecting an early on cholesterol synthesis step also that has mendelian randomization support
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
this ben pedoic acid is called an atp citrate lyase inhibitor well the first step in cholesterol synthesis is citrate native mitochondria coming out of the krebs cycle is transformed to acetyl coa which boom then goes down and becomes after it becomes hmg and then the subsequent things so this ben pedoic acid is called an acl atp citrate lyase inhibitor but it's a pro drug you swallow it it's only uptaken by the liver and it inhibits an enzyme in the liver that you can't make acetyl coa